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Objective. Attention-deﬁcit hyperactivity disorder (ADHD) is a developmental disorder characterized by a long-standing pattern
of impulsive behavior, hyperkinesia, and inattention. Psychostimulants, for example, methylphenidate, are the treatment of
choice for ADHD both in children, adolescents, and adults. Method. The eﬀect of methylphenidate on sleep structure is not
well known. We studied the eﬀect of long-acting methylphenidate on sleep in adult ADHD patients, in a naturalistic treatment
setting, using actigraphic and polysomnographic recordings. Results. One of our patients experienced manic episode after starting
methylphenidate. A wrist-worn accelerometer recording demonstrated a decrease in the duration and quality of sleep. After
discontinuation of methylphenidate treatment, the patient’s symptoms subsided and there was no need for hospital admission.
Actigraphic recording showed a decrease in the amount and quality of the patient’s sleep as triggering factor for the manic
symptoms. Conclusions. Disruptions of the sleep-wake cycle are probably important etiologic factors in mood disorders, especially
bipolar disorder. The changes in length and quality of sleep described in this case report bear close resemblance to those of patients
with a manic episode, although these symptoms were induced by methylphenidate.
Copyright © 2009 Tuuli Lahti et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Attention-deﬁcit hyperactivity disorder (ADHD) is a devel-
opmental disorder characterized by impulsive behavior,
hyperkinesia and inattention. Recent studies suggest that
there is a range of abnormalities in neurotransmission in
ADHD patients [1]. Psychiatric comorbidity is common in
adult ADHD patients [2]. In addition, other developmental
disorders, for example, dyslexia, and sleep problems are
frequent in patients with ADHD [3].
Severe ADHD symptoms are often treated with medic-
ation.Psychostimulantsareeﬀectiveinallsymptomdomains
of ADHD. Stimulants such as dextroamphetamine and met-
hylphenidate are used in the treatment of ADHD both in
children and adults. A common adverse eﬀect of meth-
ylphenidate is a sleep disturbance. In children, even short-
acting methylphenidate thrice daily increases sleep onset
latency [4]. However, in clinical experience, adult ADHD
patients with prominently hyperactive symptoms in partic-
ular appear to sleep better after a stimulant has been started.
This in mind, we assessed the night-time sleep and the daily
rest-activity cycles in adult ADHD patients before, during
andafterlong-actingmethylphenidatetreatment(Concerta).
One of the study participants, a 40-year-old man with
no prior history of bipolar disorder, experienced a manic
episode after the treatment with methylphenidate was
started. His switch from euthymia into mania was recorded
with a wrist-worn accelerometer. We present herein, for
the ﬁrst time, actigraphic recording data on a switch from
euthymia into mania induced by methylphenidate.
2. Methods
The diagnosis of ADHD was assessed with the Conners’
Adult ADHD Diagnostic Interview for DSM-IV [5] using
multiple sources of information. Mental disorders were
excluded using SCID-I and SCID-II-interviews [6, 7]. A
comprehensive neuropsychological test battery was included
in the diagnostic process. At baseline, all the patients had
a careful physical examination including laboratory tests
and a urine screen. The study protocol was approved by
the ethics committee of the Helsinki University Central2 Case Reports in Medicine
Table 1: Mean values for actigraphic parameters before and during treatment with methylphenidate.
Daily dosage and duration of treatment with methylphenidate
P a r a m e t e r 0m gf o r1 6d a y s 1 8m gf o r6d a y s 3 6m gf o r5d a y s
Sleep eﬃciency (%) 80.4 69.0 67.4
Sleeplatency(h:min) 0:4 1:2 1:1
Actual sleep time (%) 87.8 86.7 80.0
Actual wake time (%) 12.2 13.4 20.0
Mean activity score 12.1 13.5 26.5
Movement and fragmentation index 31.2 34.9 44.8
Number of minutes moving 14.1 15.7 22.3
Number of minutes immobile 86.0 84.4 77.7
Hospital, Helsinki, Finland. All the patients volunteered
for the study and signed an informed consent after the
protocol had been fully explained and before any procedure
was performed. Here, we present a case report of one of
the study participants, a 40-year-old man. He was recently
diagnosed as having ADHD, with no medication prior to
the study. The dosage was at start one tablet (18mg of
methylphenidatehydrochloride) in the morning, and after
six days of medication the daily dose was increased up
to two tablets (36mg of methylphenidatehydrochloride) in
the morning. Concomitant psychotropic medication was
not allowed during the study. The daily rest-activity cycles
were continuously recorded with a wrist-worn accelerometer
(actigraph). It gives information about the duration and
quality of sleep and the level of physical activity. He wore
the accelerometer on his nondominant hand all the time,
except during bathing or swimming, for 16 days before
starting the treatment with methylphenidate and for 11 days
(18mg for 6 days followed by 36mg for 5 days) during
the active treatment. The actigraphic variables used for the
analysis included sleep eﬃciency (the percentage of time
spent asleep whilst in bed), sleep latency (the time delay
between going to bed and falling asleep), actual sleep time
(the percentage of time spent in bed in a sleep), actual wake
time (the percentage of actual time spent awake in bed),
mean activity score (the average value of the activity counts
per epoch over the assumed sleep period), movement and
fragmentation index (indicates the restlessness of the sleep),
number of minutes moving (the total number of minutes
moving during sleep), and number of minutes immobile
(the total number of minutes immobile). The data were
analyzed with the software provided by the manufacturer
(The Actiwatch Sleep Analysis 2001, version 1.19).
3. Results
The patient’s response to methylphenidate was clinically
rated as good. In addition to alleviation of his ADHD symp-
toms, his bruxism and nail-biting activities were reduced.
However, he became increasingly more talkative and excited
during the treatment with methylphenidate. He reported
that his subjective quality of sleep was decreased, which was
conﬁrmed in the actigraphic recordings (Table 1). After dou-
bling the methylphenidate dosage from 18mg to 36mg per
day, he became more impulsive. He described experiencing a
totally new understanding of life and some kind of bonding
with the universe. He had rapid mood swings during the
days. He felt very energetic and was exceptionally active.
The diagnosis of a manic episode (substance-induced) was
assessed, when he had an appointment (per study protocol)
with one of the authors (PT). His wife was met during
the appointment and conﬁrmed the change in activity and
behavior. The patient was excluded from the study and
his treatment with methylphenidate stopped immediately.
His manic symptoms disappeared completely during the
following days, and no mood-stabilizing medication was
needed. In the actigraphic recordings, the quality and the
duration of sleep were reduced during the treatment with
methylphenidate (Table 1). Sleep eﬃciency was reduced in
proportion to the methylphenidate dose. Sleep latency was
increased, actual sleep time was decreased, and actual wake
time was increased during the treatment. All the activity
variables indicated that sleep became increasingly more
restless as the methylphenidate dose increased.
4. Conclusions
Insomnia is known to be a potential adverse eﬀect of
psychostimulants and may trigger manic episodes [8, 9].
Patients with mood disorder in particular are vulnerable
to sleep disruption, and among bipolar patients with the
comorbid ADHD the rate of the stimulant-associated hypo-
mania or mania is as high as 40% [10–15]. Our patient
had no prior history of depressive, hypomanic or manic
episodes. During a follow-up of three years, our patient has
experienced no further episodes of mood disorder, although
he is still being treated with methylphenidatehydrochloride
(mainly short-acting tablets, 20–25mg/day). However, he
has reported that occasionally, after the use of longer-acting
methylphenidate tablets for three or more consecutive days,
insomnia returns and his symptoms start to resemble those
experienced during the manic episode.
Clinical experience is that disruptions in sleep often
predict onset of mood episodes, both mania and depression.
Here, methylphenidate disrupted sleep and induced mania-
like symptoms in an adult patient with ADHD, but noCase Reports in Medicine 3
underlying mood disorder. His reaction seemed to be clearly
dose-related and dependent also on the use of long-acting
methylphenidate.
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